SEATTLE — June 10, 2011 — Swedish Heart & Vascular Institute-affiliated interventional cardiologists recently completed their first robotic-assisted coronary angioplasty (the catheter-based balloon treatment to help treat a narrowed or blocked artery) as part of the CorPath PRECISE clinical trial. The sponsored clinical trial is evaluating the safety and effectiveness of the CorPath200 System in delivering and manipulating coronary guide wires and stents in percutaneous coronary interventions (PCI) procedures. Swedish is one of only seven hospitals in the world – and the only one on the West Coast – evaluating this new investigational technology.
Coronary artery disease (CAD) is the most common form of heart disease and the leading cause of death in America. The most common treatment for CAD is a PCI procedure, commonly known as angioplasty. Traditionally, PCI procedures are performed by an interventional cardiologist in a catheterization laboratory (cath lab). The physician visualizes the coronary arteries by utilizing X-ray angiography (real-time X-ray). Miniature equipment (as small as 1/14,000 of an inch in diameter) is advanced through blockages within the coronary arteries.
“An aging baby boomer population at increased risk for CAD has driven the demand for innovative, new technologies in the cath lab. However, since I started my career, the way we perform the procedure really has not changed,” said Mark Reisman, M.D., interventional cardiologist and principal investigator of the CorPath PRECISE Trial at Swedish. “It is exciting to perform a procedure with robotic precision from the CorPath’s control cockpit.”
“I was able to easily and safely manipulate the guide wire and stent with precise millimeter-by-millimeter adjustments,” added Dr. Reisman. “I was able to completely focus on the patient’s physiology and anatomy with excellent visualization of the arteries. Implanting a stent while wearing heavy radiation protection is hopefully a thing of the past.”
Today, a traditional PCI procedure exposes the interventional cardiologist to constant radiation exposure. An interventional cardiologist’s daily exposure to radiation and the physical stresses inherent in the cath lab can lead to occupational health risks — including orthopedic problems, cataracts, cancer and fatigue according to recent data published in Catheterization and Cardiovascular Intervention journal.
The CorPath 200 System provides precise, robotic-assisted placement of coronary guide wires, angioplasty balloons and stents from an ergonomically optimized interventional cockpit. The operator is protected from radiation exposure in a lead-shielded cockpit. The comfortable seated position provides enhanced visualization of the angiography screens, while reducing fatigue and minimizing head, neck and back pain.
“We are excited to begin the CorPath PRECISE trial,” said Dr. Reisman. “We believe that improving precision of PCI procedures and the ergonomic conditions of the cath lab will ultimately improve patient care. Vascular robotics at Swedish emphasizes our continuous commitment to delivering state-of-the-art technology to our patients and clinical community.”
The trial is a prospective, single-arm, multi-center, non-randomized research study, which will enroll up to 175 patients at medical centers across the country. Swedish is one of only seven centers in the United States – and the only one on the West Coast – participating in the trial.
Swedish has grown over the last 100 years to become the largest, most comprehensive non-profit health provider in the Greater Seattle area. It is comprised of four hospital campuses; emergency departments and ambulatory care centers in Issaquah, Redmond and Mill Creek; Swedish Visiting Nurse Services; and Swedish Medical Group – a network of more than 70 primary-care and specialty clinics located throughout the Greater Puget Sound area. Swedish recently opened a new emergency department and medical office building (MOB) on its Ballard campus and will open a new MOB and hospital in Issaquah in mid-July 2011. In addition to general medical and surgical care, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research. For more information, visit www.swedish.org.
In 2007, Swedish embarked upon an ambitious $100 million fundraising campaign. Campaign investments are used to support a wide-variety of initiatives throughout the health-care system, including cancer, heart and vascular, women and children, neurosciences, and orthopedics as well as programs to support underserved populations. To date, the campaign has secured gifts totaling more than $76 million. For more information or to support the campaign, visit www.campaignforswedish.org.
About Swedish Heart & Vascular Institute
The Swedish Heart & Vascular Institute is a regional network of physicians at hospitals and clinics across the Puget-Sound area. It offers a broad spectrum of adult and pediatric cardiovascular-care services – from surgical and interventional procedures to the latest advances in heart-disease prevention, diagnosis and cardiovascular health and wellness. The institute – which is affiliated with more than 60 cardiac and vascular specialists, including cardiologists, surgeons, radiologists, anesthesiologists and vascular specialists – has a presence at Swedish’s Cherry Hill and Edmonds campuses as well as at Highline Medical Center in Burien. In addition, the Institute focuses on research and education as fundamental tools in fighting heart disease. For more information, visit www.swedish.org/heart.
Corindus is the global technology leader in robotic-assisted percutaneous coronary interventions. The Company’s CorPath® 200 System is the first investigational medical device that offers interventional cardiologists complete PCI procedure control from an interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications. NOTE: The CorPath 200 System is an investigational device and limited by federal law to investigational use only. For more information, visit www.corindus.com.